SAN DIEGO--(BUSINESS WIRE)--Dexcom, Inc. (NASDAQ:DXCM), the leader in continuous glucose monitoring for people with diabetes, announced today the U.S. Centers for Medicare & Medicaid Services (CMS) is ...

Share price of DexCom, Inc.DXCM jumped 4.8% on Aug 25, following the FDA approval of the DexCom G5 Mobile Continuous Glucose Monitoring (CGM) System. The fully portable product is the first and ...

The FDA has approved San Diego, California-based Dexcom for a Bluetooth-enabled continuous glucose monitor (CGM), called the G5 Mobile CGM system. Correction: A previous version of this article ...

This approval marks the Company’s fifth new insulin pump launch in only 5 years and the second featuring Dexcom technology. It is the only available pump that conveniently displays a user’s insulin ...

Dexcom Executive Vice President and Chief Commercial Officer RIck Doubleday visited The American Journal of Managed Care® to discuss Medicare reimbursement for the Dexcom G5 and a new partnership with ...

As expected, an FDA panel voted in favor of giving Dexcom’s ($DXCM) G5 continuous glucose monitor a nonadjunctive indication that would allow it to be used in place ...